Abstract
Even though there is an increased knowledge of the biology and neurophysiology of pain, new pain therapeutics struggle to provide efficacy and safety in the clinic. Biological therapies represent an emerging class of novel analgesics which have the potential to overcome some of the shortfalls of small molecules used for treatment of pain whose efficacy is often limited by off-target activity. Biologics, such as monoclonal antibodies, however, may offer exquisite peripheral target specificity and engagement with limited off-target toxicity